BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. | ...

The federal government is cutting 3,500 full-time FDA employees and 1,200 NIH workers as part of an overarching move designed ...

Lyndra Therapeutics, which spun out of Moderna co-founder Robert Langer’s lab at the Massachusetts Institute of Technology in ...

Schwetz’s leave will be effective as of 5 p.m. today, Stat reported yesterday. The news broke the same day that the Senate ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

According to the FDA’s public database, since the start of this year, the agency has issued only two de novo medical device ...

The restructuring is only the latest round of layoffs to hit Arbutus, after the company shed 40% of its staff and cut back on ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.